Shares of MDxHealth plunged 16.8% to $0.67 on August 17, erasing much of a 74.9% spike just three days earlier, as investors weighed a massive share sale against a quarter of genuine revenue progress. The collision of good operating news with aggressive financing paints a stark picture: a company racing to grow its way out of a cash crunch while handing existing shareholders a punishing bill.

• The Company Nearly Doubled Its Shares Outstanding to Stay Afloat

MDxHealth issued 44,052,862 new shares at $0.454 apiece, raising roughly $20 million and expanding total shares outstanding to 95.4 million — meaning legacy holders saw their ownership cut nearly in half overnight. The cash infusion lifts the company's pro forma liquidity from $19.2 million to about $39 million , buying time but at a steep cost. One buyer, Bleichroeder LP, acquired 24.2 million of those shares and now holds a 33.2% stake, subject to a 90-day lock-up — a concentrated bet that could stabilize or pressure the stock once it expires.

• Revenue Beat Estimates, but Losses Are Still Getting Worse

The company posted a loss of -$0.18 per share, beating the -$0.20 estimate, on revenue of $27.2 million, which topped forecasts by about $800,000 . Yet operating loss widened to $5.1 million and net loss ballooned to $9.5 million , largely due to costs from integrating its urine-based prostate test acquisition. The company has failed to beat EPS consensus in any of the last four quarters .

• A Nasdaq Delisting Clock Adds Urgency

MDxHealth received a Nasdaq deficiency notice on July 2 after trading below the $1.00 minimum for 30 straight days; it has until December 28, 2026 to regain compliance . A second notice flagged noncompliance with the $35 million minimum market-value rule . At $0.67 and 95 million shares, the current market cap sits around $64 million — clearing that bar for now — but a reverse stock split may still loom.

• Management's Optimism Rests on Second-Half Acceleration

MDxHealth reiterated full-year revenue guidance of $110–$115 million, implying 20–26% growth . The company targets a return to positive adjusted EBITDA — essentially, operating profit before accounting charges — by year-end . That means the back half must deliver roughly $60 million** in revenue, a steep climb that leaves no room for stumbles.